MBX Biosciences, Inc. MBX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 102.83% | 85.89% | 74.85% | 66.88% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.23% | 21.35% | 43.79% | 52.53% | -- |
| Operating Income | -36.23% | -21.35% | -43.79% | -52.53% | -- |
| Income Before Tax | -35.41% | -17.89% | -40.45% | -45.88% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.41% | -17.89% | -40.45% | -45.88% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.41% | -17.89% | -40.45% | -45.88% | -- |
| EBIT | -36.23% | -21.35% | -43.79% | -52.53% | -- |
| EBITDA | -36.37% | -21.47% | -43.94% | -52.70% | -- |
| EPS Basic | 47.07% | 86.68% | 90.74% | 92.83% | -- |
| Normalized Basic EPS | 46.53% | 86.23% | 90.47% | 92.74% | -- |
| EPS Diluted | 47.07% | 86.68% | 90.74% | 92.83% | -- |
| Normalized Diluted EPS | 46.53% | 86.23% | 90.47% | 92.74% | -- |
| Average Basic Shares Outstanding | 62.35% | 113.32% | 244.43% | 1,228.68% | -- |
| Average Diluted Shares Outstanding | 62.35% | 113.32% | 244.43% | 1,228.68% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |